30 closest matches · ranked by relevance
Advanced Nonhematological Malignancies · Non-Small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 2 participants
Hematologic Malignancies
Primary: Number of Participants With Successful Bone Marrow Engraftment — 1; 15; 1 Participants
Lymphoma · Leukemia
Primary: Composite Success Rate — 100; 75; 84 Percentage of participants
Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Extranodal Marginal Zone Lymphoma
Primary: Relapse-free Survival (RFS) — 83 months
Leukemia · Lymphoma, Non-Hodgkin
Primary: Tumor Apoptosis — 7 Participants
Advanced Nonhematologic Malignancies
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 4; 3; 7; 3 Participants
Acute Myeloid Leukemia · Lymphoblastic Leukemia · Acute Leukemia
Primary: Number of Participants With Grade 4 TMI Toxicity — 0; 0; 0; 2 Participants
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Advanced Non-hematologic Malignancies
Primary: Part 1: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 0; 1 participants
Myelodysplastic Syndrome · Multiple Myeloma · Hodgkin Lymphoma
Primary: Number of Participants Who Experienced One or More Adverse Events (AEs): — 27; 28; 31; 21 Participants
Advanced B-cell Lymphoid Malignancies
Primary: Total Number of Adverse Events. — 2 Adverse events
Non-small Cell Lung Carcinoma · Urothelial Carcinoma · Gastrointestinal Carcinoma, Non-colon
Primary: Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations — 10.3; 0; 7.1; 0 percentage of participants
Cancer
Primary: Overall Response Rate (ORR) in the Anaplastic Thyroid Cancer (ATC) Cohort — 56; 56; 53; 53 Percentage of Participants
Nonhematologic Neoplasms, Advanced
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) Assessed by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Version 4.03…
Acute Lymphoid Leukemia · Acute Myeloid Leukemia · Anemia, Refractory, With Excess of Blasts
Primary: Objective Response Rate (ORR) by Investigator — 12; 14 percentage of participants
Myelodysplastic Syndrome · Acute Myeloid Leukemia (AML) · Chronic Myeloid Leukemia (CML)
Primary: Cellular Immune Response — 4 participants
Lymphoma, Mantle-Cell
Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Day 100 TRM — 4 Participants
Ovarian Cancer · Non Small Cell Lung Cancer · Prostate Cancer
Primary: Percentage of Participants With a Complete Response (CR) or Partial Response (PR) — 0; 0; 0; 0 percentage of participants
Multiple Myeloma · Amyloidosis
Primary: Number of Participants Without Renal Allograft Rejection at 6 Months Post-transplant — 1 Participants
Hematologic Malignancies
Primary: Number of Participants With First Cycle Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Advanced Non-Hematologic Malignancies
Primary: Maximum Tolerated Dose (MTD) — NA mg/kg
Melanoma
Primary: Clinical Responses in Patients With Metastatic Ocular Melanoma — 0; 0; 9; 7 Participants
Malignant Melanoma · Head and Neck Cancer
Primary: Tissue and Hematopoietic Stem Cell Collection — 8 Participants
Carcinoma, Non-Small-Cell Lung · Colorectal Cancer · Malignant Melanoma
Primary: Number of Participants With Severe Adverse Events (AEs), Serious Adverse Events (SAEs), Drug-Related AEs, Deaths, Discontinuation of Study Drug Due to AE, Dose-Limiting…
Cervical Cancer · Renal Cancer · Urothelial Cancer
Primary: Maximum Tolerated Cell Dose (MTD) of Cluster of Differentiation 4 (CD4) Cells Transduced With an Anti-MAGE-A3-DP0401/0402 Restricted (MAGE-A3-DP4) T Cell Receptor and…
Lymphoma · Hodgkin Disease · Lymphoma, Non-Hodgkin
Primary: 68Ga-DOTANOC Uptake in Lymphomas With PET/CT — 3.1 Standardized Uptake Value
Hematologic Malignancies
Primary: Number of Participants Who Have Severe Acute Graft-versus-host-disease (GVHD) — 2; 0; 5; 1 Participants
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months